{"filings":[{"id":1922157,"accession_number":"0000875045-26-000073","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-07-29T10:10:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).","Growth Portfolio revenue $1.06B (+24% YoY); SPINRAZA $402M (+2%), LEQEMBI in-market $184M (+15%), SKYCLARYS $168M (+29%).","Apellis acquisition closed May 14; SYFOVRE $162M (Biogen $97M), EMPAVELI $46M (Biogen $30M); $0.85 dilution to Non-GAAP EPS in 2026, accretive 2027.","Pipeline: litifilimab SLE data by end-2026; diranersen proof-of-concept in Alzheimer's; pending RayThera acquisition.","Full year 2026 guidance updated reflecting stronger underlying business outlook adjusted for transactions and milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1387796,"accession_number":"0000875045-26-000068","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-07-01T20:08:37+00:00","items":["2.02"],"status":"ready","headline":"Biogen expects Q2 IPR&D charge of ~$164M ($0.95/share) and Q3 charge of $290M-$320M ($1.75-$1.95/share)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.","Q3 2026: $290M-$320M pre-tax IPR&D charge; EPS impact $1.75-$1.95 per share.","Charges relate to collaboration and license agreements, including upfront and milestone payments.","Results for Q2 2026 not finalized; subject to financial closing procedures.","Company does not forecast such expenses due to uncertainty of future transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":974596,"accession_number":"0000950157-26-000700","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-06-10T20:54:22+00:00","items":["5.07"],"status":"ready","headline":"Biogen shareholders elect all 10 director nominees and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten board nominees elected; highest vote against for Eric K. Rowinsky (28.2M against of 121.9M voted).","PricewaterhouseCoopers ratified as auditor for FY2026 with 124.6M for, 6.6M against.","Advisory say-on-pay approved with 114.2M for, 7.5M against, 9.4M broker non-votes.","Meeting held June 9, 2026; results filed on Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":974438,"accession_number":"0000950157-26-000699","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K/A","filed_at":"2026-06-10T20:49:37+00:00","items":["9.01"],"status":"ready","headline":"Biogen amends 8-K to note Apellis acquisition not significant, no financial statements required","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquisition of Apellis closed May 14, 2026; deemed not significant under Regulation S-X after further analysis.","Items 9.01(a) and (b) financial statements and pro forma information not required; prior obligation withdrawn.","All other disclosures from the Original Report regarding the merger remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78162,"accession_number":"0001193125-26-222908","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-05-14T12:31:16+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Biogen completes $5.3B Apellis acquisition; adds SYFOVRE/EMPAVELI, $41/share + CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Biogen acquired Apellis for $41/share cash plus CVRs worth up to $4/share tied to SYFOVRE net sales milestones.","Approximately 105.7M shares (82.4%) tendered; Merger completed under DGCL Section 251(h) without shareholder vote.","Biogen borrowed $2B under a new credit agreement: $1B 364-day and $1B 2-year tranches to fund the acquisition.","Apellis products EMPAVELI and SYFOVRE generated $689M net product revenue in 2025; deal expected to be accretive to Non-GAAP EPS in 2027.","Biogen will provide updated financial guidance in Q2 2026 earnings report in July."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99329,"accession_number":"0000875045-26-000042","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).","Growth products: LEQEMBI $168M (+74%), SKYCLARYS $151M (+22%), ZURZUVAE $55M (+100%), VUMERITY $179M (+29%), QALSODY $33M (+110%).","Proposed Apellis acquisition expected to close Q2 2026, accretive in 2027; Biogen to update guidance post-close.","FY2026 Non-GAAP EPS guidance $14.25-$15.25 (ex-Apellis); total revenue seen declining mid-single digit % vs 2025.","Pipeline: litifilimab Phase 2 CLE positive; SPINRAZA High Dose Regimen FDA approved; felzartamab rights in Greater China acquired."],"consensus_eps_estimate":2.8258,"consensus_eps_actual":2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":2477800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99328,"accession_number":"0000875045-26-000039","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.","Expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.19 per share.","Expense includes upfront/milestone payments and premiums on equity securities related to collaboration and license agreements.","Biogen does not forecast such costs due to uncertainty; final Q1 results not yet finalized and may differ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115266,"accession_number":"0001193125-26-134889","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Biogen to acquire Apellis for $41/share plus up to $4 CVR per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration of $41.00 per Apellis share; one CVR per share entitling holders to up to $4.00 additional.","CVR milestones: $2.00 if SYFOVRE annual net sales reach $1.5B; $2.00 if $2.0B achieved, with potential $4.00 single payment.","Tender offer condition requires >50% shares tendered; termination fee of $205M payable by Apellis in certain circumstances.","Stockholders representing ~14% of Apellis shares entered support agreement to tender in favor.","Transaction expected to close by September 30, 2026, subject to regulatory approvals and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115265,"accession_number":"0000950157-26-000280","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen Chief Legal Officer Susan H. Alexander to depart end of May 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan H. Alexander, Chief Legal Officer, will leave Biogen effective end of May 2026.","Company has initiated a search to identify the next Chief Legal Officer.","No interim successor has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115264,"accession_number":"0001193125-26-046803","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Biogen Chair Caroline Dorsa to step down; Dr. Maria C. Freire elected as new Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chair Caroline Dorsa will not stand for re-election at the 2026 Annual Meeting; decision unrelated to any disagreement.","Board elected Dr. Maria C. Freire to serve as Chair, effective after the Annual Meeting.","Dr. Freire's appointment marks an orderly transition of Board leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115263,"accession_number":"0000875045-26-000011","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.","Full year total revenue $9.9B (+2% YoY); GAAP diluted EPS $8.79; Non-GAAP EPS $15.28 above $14.50-$15.00 guidance.","Growth products up 6% YoY in Q4; LEQEMBI global in-market sales $134M (+54% YoY).","FY2026 guidance: Non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit percent vs FY2025.","Pipeline: LEQEMBI subcutaneous PDUFA May 24, 2026; litifilimab Breakthrough Therapy for CLE; high-dose SPINRAZA PDUFA Apr 3."],"consensus_eps_estimate":1.6464,"consensus_eps_actual":8.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":9890600000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115262,"accession_number":"0000875045-26-000003","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.","Estimated impact of $1.26 per diluted share on both GAAP and non-GAAP EPS.","Expense line item newly presented separately since Q1 2025.","Final Q4 2025 results not finalized; subject to closing procedures.","Company does not forecast such expenses due to uncertainty in timing and magnitude."],"consensus_eps_estimate":1.6464,"consensus_eps_actual":8.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":9890600000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131682,"accession_number":"0000875045-25-000047","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).","Launch products LEQEMBI ($121M, +82%), SKYCLARYS ($133M, +30%), ZURZUVAE ($55M) all show strong growth.","Full year 2025 revenue guidance raised to flat to +1% (constant currency); Non-GAAP EPS guided $14.50-$15.00.","Pipeline: LEQEMBI IQLIK approved, high-dose nusinersen resubmitted (PDUFA Apr'26), litifilimab Phase 3 fully enrolled (data H2'26)."],"consensus_eps_estimate":3.9595,"consensus_eps_actual":9.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":7611200000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131681,"accession_number":"0000875045-25-000040","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen expects ~$2M pre-tax IPR&D charge for Q3, impact of ($0.01)/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary estimate: acquired IPR&D, upfront & milestone expense of ~$2M pre-tax.","Estimated impact of ($0.01) per diluted share on both GAAP and non-GAAP EPS.","Q3 2025 results not yet finalized; subject to closing procedures and could differ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148250,"accession_number":"0000875045-25-000035","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).","Raised FY2025 Non-GAAP EPS guidance to $15.50-$16.00 (from $14.50-$15.50); revenue now expected ~flat vs 2024.","LEQEMBI U.S. in-market sales ~$63M (+20% sequential); global ~$160M incl. $35M one-time China shipment.","SKYCLARYS global rev. ~$130M; U.S. ~$78M (+13% seq.); ZURZUVAE $46M (+68% seq.).","Pipeline: salanersen advancing to registrational stage in SMA; felzartamab Phase 3 initiated in rare kidney diseases."],"consensus_eps_estimate":3.9375,"consensus_eps_actual":5.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":5076500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148249,"accession_number":"0000875045-25-000027","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.","GAAP and non-GAAP diluted EPS impact of approximately ($0.26) per share.","Charge covers upfront and milestone payments from collaboration/license agreements.","Biogen does not forecast such expenses due to uncertainty in timing and magnitude.","Q2 2025 results not finalized; subject to closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167020,"accession_number":"0000875045-25-000023","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biogen stockholders elect all 11 director nominees, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 nominees elected to one-year terms; Caroline Dorsa received the most votes against (25.5M).","Ratification of PwC as auditor for FY 2025 passed with 120.1M for, 5.9M against.","Say-on-pay advisory vote approved with 78.5M for, 37.1M against (68% approval excluding broker non-votes).","Meeting held June 17, 2025; results reflect standard governance items without any contested matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167019,"accession_number":"0001193125-25-117854","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biogen issues $1.75B in three tranches of senior notes to refinance maturing 2025 debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$400M 5.050% notes due 2031, $650M 5.750% notes due 2035, $700M 6.450% notes due 2055.","Net proceeds, with cash on hand, will retire the outstanding $1.75B 4.050% Senior Notes due 2025.","Notes are senior unsecured; redeemable at par plus make-whole; 101% change-of-control put.","Underwriters: BofA Securities, Citigroup Global Markets, J.P. Morgan Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167018,"accession_number":"0000875045-25-000014","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.","LEQEMBI global in-market sales ~$96M; SKYCLARYS global revenue ~$124M; launch products more than doubled YoY.","Updated FY2025 non-GAAP EPS guidance $14.50-$15.50; total revenue expected to decline mid-single-digit constant currency.","Felzartamab Phase 3 study initiated in antibody-mediated rejection; BIIB080 (tau ASO) received FDA Fast Track designation.","Zorevunersen collaboration with Stoke ($165M upfront) for Dravet syndrome; pivotal Phase 3 to start in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2431000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184399,"accession_number":"0000875045-25-000004","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).","Full year 2024 revenue $9.7B (-2% YoY); non-GAAP EPS $16.47 (+12% YoY).","LEQEMBI global in-market sales ~$87M; SKYCLARYS revenue ~$102M, patient count nearly doubled vs end 2023.","Regulatory milestones: LEQEMBI subcutaneous BLA accepted (PDUFA Aug 31, 2025); nusinersen higher dose filings accepted (PDUFA Sep 22, 2025).","FY2025 guidance: non-GAAP diluted EPS $15.25-$16.25; total revenue to decline mid-single digit % at constant currency."],"consensus_eps_estimate":null,"consensus_eps_actual":11.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":9675900000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184398,"accession_number":"0001193125-25-006578","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen appoints Sean Godbout as Chief Accounting Officer effective March 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sean Godbout to succeed Robin Kramer as CAO and principal accounting officer; Kramer transitions to CFO role upon McDonnell's retirement.","Michael McDonnell to retire as CFO on March 1, 2025; Kramer previously announced as successor.","Godbout, age 50, internal promotion from Global Corporate Controller (since Oct 2023), joined Biogen in 2007.","Base salary $400,000; annual bonus target 40% of base; eligible for long-term incentive grants and executive severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200998,"accession_number":"0001193125-24-247628","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biogen CFO Michael McDonnell to retire Feb 2025; Robin Kramer named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael McDonnell to retire as CFO effective February 28, 2025, after serving since August 2020.","Robin Kramer, current Chief Accounting Officer, appointed CFO effective upon McDonnell's retirement.","Kramer's base salary $750,000; target bonus 80% of base; 2025 target LTI grant $3.75 million.","Kramer joined Biogen in 2018, served as CAO since 2020, also leads Treasury, procurement, and global business services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200997,"accession_number":"0000875045-24-000030","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.","Non-GAAP diluted EPS $4.08 (-6% YoY); FY2024 Non-GAAP EPS guidance raised to $16.10-$16.60 (~11% growth at midpoint).","LEQEMBI global in-market sales ~$67M (US $39M); other launches delivered sequential revenue growth.","Dapirolizumab pegol Phase 3 met primary endpoint in SLE; second Phase 3 study to initiate in 2024.","Nusinersen higher dose showed statistically significant improvement; global regulatory submissions planned."],"consensus_eps_estimate":null,"consensus_eps_actual":9.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":7221200000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217005,"accession_number":"0001193125-24-217633","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen elects Dr. Lloyd Minor and Prof Sir Menelas Pangalos to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased; Dr. Lloyd Minor effective Oct 1, 2024; Prof Sir Mene Pangalos effective Jan 1, 2025.","Both directors serve until 2025 Annual Meeting; receive standard non-employee director compensation.","Each will enter into indemnification agreement on same terms as other directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217004,"accession_number":"0001193125-24-200660","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Biogen enters $1.5B unsecured revolving credit facility, terminates prior facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B five-year unsecured revolving credit facility; no borrowings drawn at closing.","Replaces 2020 credit agreement; no outstanding loans at termination.","Interest rates based on credit ratings: Term SOFR + 0.625%-1.375%; commitment fee 0.05%-0.15%.","Financial covenant: max consolidated leverage ratio of 3.75:1 (4.25:1 after material acquisition).","Matures August 2029, includes $25M letter of credit sublimit, $20M swing line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217003,"accession_number":"0000875045-24-000022","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).","Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).","SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.","Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).","Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":6.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":4755400000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236759,"accession_number":"0001193125-24-167938","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Biogen shareholders approve officer exculpation amendment and elect nine directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Amendment filed to allow officer exculpation to extent permitted by Delaware law; approved with 103.1M votes for, 16.3M against.","All nine director nominees elected with wide margins; Monish Patolawala received 119.1M votes for, highest count.","Ratification of PwC as independent auditor for FY2024: 123.7M for, 5.3M against.","Advisory vote on executive compensation passed with 114.4M for, 5.1M against.","Adoption of 2024 Omnibus Equity Plan and 2024 Employee Stock Purchase Plan both approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236758,"accession_number":"0000875045-24-000012","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q1 EPS up 8% non-GAAP; LEQEMBI sales triple Q4 to $19M; reaffirms FY guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $2.3B (-7% YoY); GAAP diluted EPS $2.70 (+1%); Non-GAAP diluted EPS $3.67 (+8%).","LEQEMBI global in-market sales ~$19M, nearly triple Q4 2023; patients on therapy up ~2.5x since end 2023.","SKYCLARYS Q1 global revenue $78M; U.S. launch progressing, E.U. launch underway.","Full-year 2024 guidance reaffirmed: Non-GAAP EPS $15-16 (mid-point ~5% growth); operating margin improvement expected.","SPINRAZA U.S. revenue +1%, outside U.S. impacted by competition and shipment timing."],"consensus_eps_estimate":null,"consensus_eps_actual":2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":2290500000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254375,"accession_number":"0000875045-24-000004","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05","Full year 2023 revenue $9.8B (-3% YoY); GAAP EPS $7.97 vs $20.87; Non-GAAP EPS $14.72 vs $17.67","EPS negatively impacted by $0.35 from ADUHELM closeout costs; LEQEMBI co-promotion announced","2024 guidance: Non-GAAP EPS $15.00-$16.00 (~5% growth vs 2023); revenue expected down low- to mid-single digit","SKYCLARYS launched with ~1,000 patients; ZURZUVAE postpartum depression launch; 'Fit for Growth' $1B gross savings by 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":7.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":9835600000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271864,"accession_number":"0001193125-23-293433","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Biogen amends bylaws to update stockholder notice requirements and align with SEC universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Requires disclosure of derivative/synthetic long positions from stockholders proposing business or nominations.","Aligns director nomination procedures with Rule 14a-19, including 67% proxy solicitation representation requirement.","Limits number of nominees a stockholder may propose to number of directors to be elected at meeting.","Requires stockholder proxy solicitations to use non-white proxy cards; white cards reserved for Board use.","Updates adjournment, quorum, and stockholder list provisions to conform to recent Delaware law changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271863,"accession_number":"0001193125-23-273579","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biogen elects Monish Patolawala to board effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monish Patolawala elected as director to fill a vacancy; term expires at 2024 Annual Meeting.","Patolawala qualifies as an audit committee financial expert; expected to join Audit Committee.","He will enter into standard indemnification agreement with Biogen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271862,"accession_number":"0000875045-23-000035","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).","LEQEMBI FDA approval for Alzheimer's, ZURZUVAE for PPD approved; Reata acquisition closed.","Fit for Growth cost savings program of $1B initiated to improve bottom line.","Full-year 2023 guidance updated; new launches expected to drive growth.","Subcutaneous LEQEMBI and tau-directed ASO (BIIB080) show clinical potential."],"consensus_eps_estimate":null,"consensus_eps_actual":6.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":7449300000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288705,"accession_number":"0001193125-23-245816","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K/A","filed_at":"2023-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biogen Board adopts annual Say-on-Pay vote after stockholder advisory vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted in favor of annual Say-on-Pay frequency at June 26, 2023 annual meeting.","Board determined future Say-on-Pay votes will be conducted every year.","Board will re-evaluate frequency after next Say-on-Frequency vote, no later than 2029 annual meeting.","This amendment to the 8-K solely addresses the Say-on-Frequency determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288710,"accession_number":"0001193125-23-242617","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biogen completes Reata acquisition; SKYCLARYS launch underway in U.S.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired SKYCLARYS (omaveloxolone), first FDA-approved treatment for Friedreich's ataxia.","Over 1,000 patient start forms submitted in the U.S. since launch; EU review ongoing.","Deal expected slightly dilutive to Non-GAAP EPS in 2023, neutral in 2024, accretive from 2025.","Biogen to update 2023 financial guidance with Q3 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288709,"accession_number":"0001193125-23-227692","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Biogen secures $1.5B term loan to fund Reata acquisition; bridge loan canceled","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B unsecured term loan facility split into $750M 364-day Tranche A and $750M 3-year Tranche B.","Proceeds to pay part of Reata buyout, repay existing Reata debt, and cover transaction fees.","Interest rates: Term SOFR + 1.250%-1.625% or Base Rate + 0.250%-0.625%, based on debt ratings.","Financial covenant of 3.5x max leverage, temporarily rising to 4.0x upon merger close.","Prior $1.5B 364-day bridge loan commitment from JPMorgan terminated and canceled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288708,"accession_number":"0001193125-23-198542","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Reata for $172.50 per share cash; Reata board unanimously approved.","Biogen obtained $1.5B bridge loan commitment from JPMorgan to help finance the deal.","Transaction expected to close by Jan 28, 2024, subject to Reata stockholder approval and regulatory clearances.","Termination fees: $264M payable by Reata (if it terminates for a superior proposal) and $301M payable by Biogen.","Support agreements with certain Reata stockholders to vote shares in favor of the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288707,"accession_number":"0001193125-23-196808","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biogen to acquire Reata for $172.50/share, ~$7.3B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal price $172.50/share in cash; total enterprise value ~$7.3 billion.","Expected closing in Q4 2023; subject to Reata stockholder approval and regulatory clearances.","Biogen to finance with cash on hand plus term debt; voting agreements cover ~36% of Reata shares.","Acquisition expected to be slightly dilutive to Biogen non-GAAP EPS in 2023, neutral in 2024, significantly accretive from 2025.","Reata's SKYCLARYS is the first FDA-approved treatment for Friedreich's ataxia; launch underway, EU review ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288706,"accession_number":"0000875045-23-000027","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue $2.46B (-5% YoY); launches LEQEMBI, announces net $700M cost savings by 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $2,456M; GAAP EPS $4.07, non-GAAP EPS $4.02; EPS down 44% and 23% YoY respectively.","Launched Alzheimer's drug LEQEMBI in U.S. during Q2.","Fit for Growth program: ~$1B gross savings, ~$300M reinvested, net ~$700M by 2025; ~1,000 headcount reduction.","TECFIDERA EU regulatory protection extended to Feb 2, 2025; new SPINRAZA data in SMA post gene therapy.","Reaffirmed full-year 2023 guidance; R&D pipeline prioritization substantially complete."],"consensus_eps_estimate":null,"consensus_eps_actual":6.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":4919000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309348,"accession_number":"0000875045-23-000024","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Biogen shareholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven incumbent directors re-elected; Susan K. Langer elected with 64M for, 46.6M against, 8.5M abstentions.","Ratification of PricewaterhouseCoopers as independent auditor for FY2023 approved with 123.4M for, 4.3M against.","Advisory vote on executive compensation approved with 82.6M for, 36.3M against.","Advisory frequency vote set at every one year with 115.8M votes for 1-year.","Broker non-votes of 8.7M shares reported on director elections and compensation items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309347,"accession_number":"0001193125-23-133476","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EU extends Tecfidera market exclusivity to Feb 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission notified Biogen that Tecfidera's regulatory market protection extends to February 2, 2025.","The extension provides longer exclusivity for Biogen's multiple sclerosis drug, delaying generic competition.","Tecfidera contributed significant revenue; this decision supports Biogen's near-term cash flows."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309346,"accession_number":"0000875045-23-000012","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen posts Q1 GAAP EPS $2.67, non-GAAP $3.40; reaffirms FY23 guidance; multiple regulatory milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).","LEQEMBI Alzheimer's drug: FDA Accelerated Approval, traditional filing Priority Review; PDUFA July 6, 2023.","Zuranolone depression NDA accepted with Priority Review; PDUFA Aug 5, 2023.","Tofersen SOD1-ALS PDUFA date April 25, 2023; Advisory Committee backed surrogate endpoint.","Appointed Chuck Triano (IR) and Adam Keeney (Corporate Dev); cost optimization program initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2463000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309345,"accession_number":"0001193125-23-105074","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Biogen amends bylaws to change 'Chairman' title to 'Chair'","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Fourth Amended and Restated Bylaws effective April 12, 2023.","Title change from 'Chairman' to 'Chair' adopted in corporate governance documents.","No impact on financial position, operations, or leadership roles beyond nomenclature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328075,"accession_number":"0001193125-23-064961","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Biogen Chair Stelios Papadopoulos to step down; Caroline D. Dorsa elected as new Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stelios Papadopoulos will not stand for re-election at the 2023 Annual Meeting; departure unrelated to any disagreement with Board or Company.","Board elected Caroline D. Dorsa to serve as Chair of the Board, effective after the Annual Meeting.","Papadopoulos' decision is a planned succession; no operational or policy disputes cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328074,"accession_number":"0000875045-23-000005","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.","FY2022 revenue $10,173M (-7% YoY); GAAP EPS $20.87; Non-GAAP EPS $17.67 (-8% YoY).","FY2023 guidance: mid-single digit revenue decline; Non-GAAP EPS $15.00-$16.00.","LEQEMBI (lecanemab) granted FDA accelerated approval; traditional filing submitted in US, EU, Japan, China.","Zuranolone NDA for MDD/PPD accepted with Priority Review; PDUFA date August 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":20.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":10173400000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345732,"accession_number":"0001193125-22-281950","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biogen appoints Christopher Viehbacher as President and CEO effective Nov 14, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Viehbacher succeeds Michel Vounatsos, who steps down as CEO and from the Board.","Viehbacher receives $1.6M base salary, 150% target bonus, and initial equity awards totaling $28M (options + PSUs).","He must purchase at least $2M of Biogen stock; then receive an RSU grant of $2M vesting in 3 years.","Severance: 1.5x salary plus target bonus if terminated without cause or for good reason; 2x if change in control.","Viehbacher co-founded Gurnet Point Capital, former global CEO of Sanofi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345731,"accession_number":"0000875045-22-000028","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2022-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).","GAAP diluted EPS $7.84; Non-GAAP diluted EPS $4.77.","Lecanemab Phase 3 Clarity AD met primary endpoint and all key secondary endpoints in early Alzheimer's.","Tofersen NDA accepted with priority review; PDUFA date April 25, 2023.","Company raises full year 2022 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":17.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7629400000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362143,"accession_number":"0000875045-22-000020","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2022-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).","GAAP diluted EPS $7.24; Non-GAAP diluted EPS $5.25.","FDA granted Priority Review for lecanemab (Alzheimer's) with decision by Jan 6, 2023; Phase 3 data expected Fall 2022.","Second positive Phase 3 for zuranolone in PPD; joint U.S. filing for MDD and PPD expected H2 2022.","Launched BYOOVIZ (biosimilar Lucentis) in U.S.; raised full year 2022 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":9.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":5120900000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362142,"accession_number":"0000875045-22-000023","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K/A","filed_at":"2022-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.","MS revenue $1,719M (-4% YoY); SPINRAZA $431M (-14%); Biosimilars $194M.","FDA Priority Review for lecanemab in early Alzheimer's; decision by Jan 6, 2023; Phase 3 data expected Fall 2022.","Positive Phase 3 for zuranolone in PPD; joint US filing for MDD and PPD expected H2 2022.","Company raises full year 2022 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":9.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":5120900000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381663,"accession_number":"0001193125-22-177791","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Biogen EVP Chirfi Guindo to depart June 30; say-on-pay passes with 48% against","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chirfi Guindo, EVP Global Product Strategy, leaves June 30, 2022 for a role outside Biogen.","All 11 director nominees elected; Richard Mulligan received 77.4M for, 38.3M against.","PwC ratified as 2022 auditor with 123.8M votes for and 2.3M against.","Advisory say-on-pay approved: 60.1M for, 55.3M against (47.9% against), indicating shareholder concern.","No other material changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381662,"accession_number":"0000875045-22-000013","cik":875045,"company_name":"BIOGEN INC.","ticker":"BIIB","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Biogen Q1 revenue down 6%, EPS miss; CEO Michel Vounatsos to step down; ADUHELM infrastructure cut","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Q1 revenue $2.532B (-6% YoY); GAAP EPS $2.06, Non-GAAP EPS $3.62, both impacted by $0.76 ADUHELM write-offs","Company to eliminate most ADUHELM commercial infrastructure after negative Medicare coverage decision","Completed sale of biosimilar JV stake for up to $2.3B in April; reaffirmed 2022 financial guidance","CEO Michel Vounatsos to step down; search for successor underway; he remains CEO during interim period"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28951638524.73777,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-03T23:59:59+00:00|381662"}